TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
81 hedge funds and large institutions have $45.1M invested in TCR2 Therapeutics Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 29 reducing their positions, and 13 closing their positions.
166% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $429K
0.3% more ownership
Funds ownership: 64.56% → 64.86% (+0.3%)
2% less funds holding
Funds holding: 83 → 81 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
38% less capital invested
Capital invested by funds: $72.2M → $45.1M (-$27.1M)
48% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 29
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.38M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$570K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$410K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$290K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$287K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$1.23M |
| 2 |
Charles Schwab
San Francisco,
California
|
-$514K |
| 3 |
JP Morgan Chase
New York
|
-$505K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$479K |
| 5 |
NM
Newtyn Management
New York
|
-$269K |
TCRR Hedge Fund Activity: Q3 2022 in Review
81 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q3 2022, worth a combined $45.1M — down 38% from $72.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TCRR and 11 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 15 added.
The largest buyer was K2 Principal Fund, adding an estimated $2.38M. The largest seller was D.E. Shaw & Co, cutting an estimated $1.23M.
- 81 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q3 2022, down from 83 in Q2 2022.
- Funds reported $45.1M of TCR2 Therapeutics Inc. Common Stock stock for Q3 2022, down 38% quarter-over-quarter.
- 11 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q3 2022 and 13 closed out, a net change of -2 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q3 2022 was K2 Principal Fund, an estimated $2.38M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q3 2022 was D.E. Shaw & Co, an estimated $1.23M sold.
Based on aggregated 13F filings for Q3 2022.